Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Neil Bifulco
Observed names:
N. Bifulco,
Neil Bifulco Jr.
Institution:
Recludix Pharma (United States)
Observed institutions:
Blueprint Medicines (United States),
GlaxoSmithKline (United States),
Recludix Pharma (United States),
University at Buffalo, State University of New York
OpenAlex ID:
A5089979299
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
2015
·
Margit Hagel
, Chandra Miduturu
, et al.
·
Cancer Discovery
·
342
PDF
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
2017
·
Thomas F. Durand-Réville
, Satenig Guler
, et al.
·
Nature Microbiology
·
311
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
2019
·
Megan A. Hatlen
, Oleg Schmidt-Kittler
, et al.
·
Cancer Discovery
·
121
Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors
2003
·
Wieslaw Kazmierski
, Neil Bifulco
, et al.
·
Bioorganic & Medicinal Chemistry
·
115
The design, synthesis and activity of non-ATP competitive inhibitors of pp60c-src tyrosine kinase. Part 2: Hydroxyindole derivatives
2000
·
Karen L Milkiewicz
, Thomas H Marsilje
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
31
Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma
2022
·
Stefanie S. Schalm
, Erin O’Hearn
, et al.
·
Gastro Hep Advances
·
21
PDF
Abstract 2306: BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models
2022
·
Victoria Brown
, Phil Ramsden
, et al.
·
Cancer Research
·
15
Substituted indanylacetic acids as PPAR-α–γ activators
2005
·
Derek B. Lowe
, Neil Bifulco
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
14
Abstract P6-10-07: CDK2 inhibition with BLU-222 in combination with ribociclib demonstrates robust antitumor activity in pre-clinical models of CDK4/6 inhibitor-naïve and -resistant HR+/HER2- breast cancer
2023
·
Victoria Brown
, Nealia House
, et al.
·
Cancer Research
·
13
Corrigendum to “Recent Progress in Discovery of Small–Molecule CCR5 Chemokine Receptor Ligands as HIV-1 Inhibitors” [Bioorg. Med. Chem. 2003, 11, 2663–2676]
2003
·
Wieslaw Kazmierski
, Neil Bifulco
, et al.
·
Bioorganic & Medicinal Chemistry
·
9
Abstract 1279: Development of a selective CDK2-E inhibitor in CCNE driven cancers
2021
·
Yoon J. Choi
, Steve Wenglowsky
, et al.
·
Cancer Research
·
8
Abstract LB-324: First isoform selective inhibitor of FGFR4 for the treatment of genomically defined patients with hepatocellular carcinoma
2014
·
Margit Hagel
, Chandra Miduturu
, et al.
·
Cancer Research
·
5
First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway
2015
·
K. Hoeflich
, M. Hagel
, et al.
·
Journal of Hepatology
·
1
First-in-class potent and selective dual STAT1/3 inhibitors optimized for topical treatment of dermatologic inflammatory diseases
2026
·
A. Moreno
, R. Vaswani
, et al.
·
Journal of Investigative Dermatology
Novel inhibitors of the scaffolding function of BTK selectively and potently block BTK signaling and are efficacious in preclinical models of chronic spontaneous urticaria
2025
·
M.A. Eckert
, K. Cohen-Katsenelson
, et al.
·
Journal of Investigative Dermatology
Oral selective STAT3 inhibitors demonstrate differentiated efficacy and safety potential in preclinical models of Th17 mediated skin inflammation
2024
·
A.K. Gardino
, N. Bifulco
, et al.
·
Journal of Investigative Dermatology
PDF
Supplementary Methods, Figure Legends from First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
2023
·
Margit Hagel
, Chandra Miduturu
, et al.
Supplementary Figures S1 - S6, Tables S1 - S2 from First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
2023
·
Margit Hagel
, Chandra Miduturu
, et al.
Data from First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
2023
·
Margit Hagel
, Chandra Miduturu
, et al.
Discovery of BLU-847: Potent, highly selective inhibitor of the tropomysin receptor kinases TRKA, TRKB and TRKC, with in vivo activity against key clinical resistance mutations
2020
·
Steve Wenglowsky
, Neil Bifulco
Discovery of BLU-847: Potent, highly selective inhibitor of the tropomysin receptor kinases TRKA, TRKB and TRKC, with in vivo activity against key clinical resistance mutations
2020
·
Steve Wenglowsky
, Neil Bifulco
Abstract A118: Identification of resistance mechanisms to FGFR4 targeted therapy in hepatocellular carcinoma
2019
·
Megan A Hatlen
, Oleg Schmidt-Kittler
, et al.
·
Molecular Cancer Therapeutics
Abstract B127: Evaluating PRKACA as a therapeutic target for Fibrolamellar Carcinoma
2019
·
Stefanie S Schalm
, Erin O’Hearn
, et al.
·
Molecular Cancer Therapeutics
Crystal Structure of FGFR4 with an Irreversible Inhibitor
2014
·
J.L. Kim
, C. Miduturu
, et al.
·
Worldwide Protein Data Bank
Recent Progress in Discovery of Small‐Molecule CCR5 Chemokine Receptor Ligands as HIV‐1 Inhibitors
2003
·
Wieslaw Kazmierski
, Neil Bifulco
, et al.
·
ChemInform
Show more works
View as search
Works count:
27
Citation count:
1,006
H-index:
9
I10-index:
9
Year
Topic
Type